4830 T3D4775 Fenofibrate An antilipemic agent which reduces both cholesterol and triglycerides in the blood. 49562-28-9 3339 C20H21ClO4 White powder. 80.5°C 0.25mg/ml at 25°C Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Route of Elimination: Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces. Half Life: 20 hours LD<sub>50</sub>=1600 mg/kg (Oral, in mice) No indication of carcinogenicity to humans (not listed by IARC). For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb) Investigated as a teratogen and reproductive hazard. 2014-09-11T05:16:04Z 2014-12-24T20:26:57Z Fenofibrate C07586 5001 DB01039 true CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1 C20H21ClO4 InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 InChIKey=YMTINGFKWWXKFG-UHFFFAOYSA-N 360.831 360.112836867 Exogenous Solid 5.3 HMDB15173 CHEMBL672 3222 <p>Jean-Francois Boyer, &#8220;Medicine based on fenofibrate, and a method of preparing it.&#8221; U.S. Patent US4800079, issued January, 1988.</p>